
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is viewed favorably because its lead asset, COYA 302, is advancing in a high-unmet-need ALS program with full enrollment of 120 participants in the ALSTARS Phase 2/3 trial, FDA Fast Track designation, and top-line data expected in early 2Q27. The investment case is strengthened by the company’s Treg-modulation thesis, supported by prior preclinical and clinical signals of improved Treg health, reduced systemic inflammation, and positive early ALS and FTD biomarker and function data, including a Phase 2 ALS study and an FTD IND accepted for Phase 2a initiation in 2H26. Financially, Coya reported a net loss of $6.6M in 2Q26 and held $43.2M in cash and cash equivalents, with management guiding runway into 2H27, giving it time to reach key catalysts before needing additional capital.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company whose valuation depends heavily on unproven programs, so any clinical or regulatory setback could sharply reduce the prospects for its Treg-based therapies. The company faces multiple fundamental risks, including failure to demonstrate clinically meaningful efficacy, delays or refusal of approval in the U.S. and/or EU, and slower-than-anticipated market penetration of COYA 302 in ALS, all of which could impair future commercialization. It also may require additional capital to fund operations, and such financing could be unavailable or substantially dilutive, while competitive, reimbursement, and partnership risks further weaken the investment case.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Coya Therapeutics Inc (COYA) Forecast
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares